 So, hi, thank you very much for the invitation from the organizing committee. I'm Christiane D'Ancerot, I'm the CEO and co-founder of Perceive AI, which is a precision medicine company applying AI to discover new biomarkers, precise biomarkers for various disease. One of the focus currently that we are, one of the pathology that we are very interested right now is early prediction of Alzheimer's disease and finding subjects that will progress to dementia in the near future for population enrichment in clinical trials. So, to give you an idea a little bit of what is the concept of precision medicine for those of you who are not familiar with that, is to change a bit the paradigm of a one-size-fetal treatment for a patient and considering that every disease, let's say one large disease like cancer or Alzheimer is a whole disease and it probably is more like sub-disease. So, the concept of precision medicine is to try to divide that and try to find the right treatment for the right patient at the right time. Obviously, it's a very complex task and that's why we are using or leveraging artificial intelligence and deep learning precisely to tackle that task. So, the first application of the company is in Alzheimer's disease. One of the reasons for that, I was asked to talk a little bit about my background. So, I'm coming from academia. I finished my PhD in computer science from University of Montreal at the end of 2007. And since then, I co-founded the company Perceive AI at the beginning of the year. I was coming from a lab that is very open science minded and obviously the transition from that kind of lab where everything is open source, open data was quite another paradigm, let's say. But very interesting and I'm very eager to discuss that with the other panelists later on. So, yeah, I think it gives you an overview a little bit of what we are doing. So, the next person.